CG01-GMP plasmids released - Ready to start GMP production of CG01

Cobra Biologics (Cobra), the gene therapy division of Cognate BioServices, a Charles River
Laboratories International, Inc. company and CombiGene AB (publ) (CombiGene), the leading gene
therapy company in the Nordic region, today announce that they have successfully completed the
production and quality assurance of the plasmids to be used in the GMP production of CG01, for
CombiGene's gene therapy for the treatment of drug-resistant focal epilepsy.

Read the press release in full

Mike Austin, Corporate Vice President, Global Operations Cell and Gene Therapy CDMO, Charles River,
comments: “We are pleased to continue the journey with CombiGene and the release of the GMP
plasmids represents a crucial step in the production of CG01. We have a well-established plasmid
production platform and in-house expertise in quality control that will ensure the delivery of GMP quality
plasmid.”